Dexcom CEO on the company’s stock performance and how Covid-19 has changed his business

Kevin Sayer, CEO of glucose monitoring systems developer for diabetes management Dexcom, joins CNBC’s “The Exchange” to talk about the company’s stock performance and how has coronavirus changed the business.
04:04
Thu, Aug 13 20201:54 PM EDT